Dr. Nikhil Mukhi, MD

Dr. Mukhi practices at Warren Clinic Inc in Tulsa, Oklahoma.

Dr. Mukhi's NPI, 1083920425, was assigned on August 24, 2010. Dr. Mukhi holds Oklahoma license 35006.

Dr. Mukhi's primary practice is Warren Clinic Inc, at 6600 S Yale E Ave, Tulsa, OK 74136 in Tulsa County. The practice phone is (918) 488-6001.

Dr. Mukhi's primary practice is Warren Clinic Inc in Tulsa, Oklahoma. Dr. Mukhi is also affiliated with Saint Francis Hospital. The medical group on file is Warren Clinic. Dmand AI also links Dr. Mukhi to 4 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mukhi practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mukhi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Mukhi's licenses on file in 2 states: Oklahoma and Mississippi.

CMS data shows 3,450 Medicare services from Dr. Mukhi across 10 procedure codes in 2024, for 470 Medicare patients. Medicare paid $171,802 for them.

CMS counts 470 Medicare patients who saw Dr. Mukhi in 2024. The largest group is 65 to 74, with 212 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 12% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mukhi's median patient age at 72, with 52% women.

In 2024, Dr. Mukhi wrote 2,177 Medicare Part D claims for 318 patients. 77% of them were for generic drugs. CMS names the drug for 1,825 of them, across 52 drugs with 11 or more claims each, at $2,736,906 in total drug cost. In 2023, CMS named 1,551 claims across 46 drugs.

Dr. Mukhi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mukhi as offering telehealth.

Dmand AI links 8 papers to Dr. Mukhi, published from 2012 to 2022. 2013 was the busiest year, with 3. The most frequent topics are Protein Kinase Inhibitors. Dr. Mukhi has published most often in J Hematol Oncol. Dr. Mukhi's most frequent co-authors are Muhammad Furqan, MD, Ridhi Gupta, MD and Samir Shankar Ambrale, MD.

CMS Open Payments shows 241 general payments to Dr. Mukhi from 32 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 84% of the total. Novartis Pharmaceuticals Corporation paid the most, $787.